Impact of a phone follow-up program on persistence with teriparatide or PTH(1-84) treatment

Calcified Tissue International

Volumn 90, Issue 4, 2012, Pages 272-278

  Tamone, Cristina ^a   Fonte, Gianfranco ^a   Panico, Anna ^a   Molinatti, Pia Anna ^a   D'Amelio, Patrizia ^a   Isaia, Giovanni Carlo ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Adherence; Osteoporosis; Persistence; PTH(1 84); Teriparatide

Indexed keywords

PARATHYROID HORMONE; PARATHYROID HORMONE[1-34];

ACUTE KIDNEY FAILURE; AGED; ARTHRALGIA; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; GUILLAIN BARRE SYNDROME; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; MALE; NURSE; OSTEOPOROSIS; PATIENT EDUCATION; PHONE FOLLOW UP PROGRAM; PRIORITY JOURNAL; SELF INJECTION; SKIN DISEASE; SURVIVAL RATE; TACHYCARDIA;

AGED; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PARATHYROID HORMONE; TELEPHONE; TERIPARATIDE;

EID: 84859889725     PISSN: 0171967X     EISSN: 14320827     Source Type: Journal    
DOI: 10.1007/s00223-012-9574-9     Document Type: Article

References (23)

1. RM Neer CD Arnaud JR Zanchetta R Prince GA Gaich JY Reginster AB Hodsman EF Eriksen S Ish-Shalom HK Genant O Wang BH Mitlak 2001 Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis N Engl J Med 344 1434 1441 11346808 10.1056/ NEJM200105103441904 1:CAS:528:DC%2BD3MXktVSgsbw%3D (Pubitemid 32402100)
2. SL Greenspan HG Bone MP Ettinger DA Hanley R Lindsay JR Zanchetta CM Blosch AL Mathisen SA Morris TB Marriott 2007 Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial Ann Intern Med 146 326 339 17339618 (Pubitemid 351650593)
3. JA Cramer MM Amonkar A Hebborn R Altman 2005 Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis Curr Med Res Opin 21 1453 1460 16197664 10.1185/030079905X61875 1:CAS:528:DC%2BD2MXhtFKqu7zP (Pubitemid 41368578)
4. V Rabenda R Mertens V Fabri J Vanoverloop F Sumkay C Vannecke A Deswaef GA Verpooten JY Reginster 2008 Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women Osteoporos Int 19 811 818 17999022 10.1007/s00198-007-0506-x 1:CAS:528:DC%2BD1cXltFyjurs%3D
5. A Cano 1994 Compliance to hormone replacement therapy in menopausal women controller in a third level academy centre Maturitas 20 91 99 7715479 10.1016/0378-5122(94)90004-3 1:STN:280:DyaK2M3jtFehtg%3D%3D
6. JA Kotzan BC Martin WE Wade 1999 Persistence with oestrogen therapy in a postmenopausal Medicaid population Pharmacotherapy 19 363 369 10221376 10.1592/phco.19.4.363.30935 1:STN:280:DyaK1M3js1Gltw%3D%3D (Pubitemid 29118179)
7. C Turbí G Herrero-Beaumont JC Acebes A Torrijos J Graña R Miguélez J Sacristán F Marín 2004 Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: an open-label, prospective, nonrandomized, observational study Clin Ther 26 245 256 15038947 10.1016/S0149-2918(04)90023-9 (Pubitemid 38339016)
8. Ziller V, Wetzel K, Hadji P (2010) Adherence and persistence in patients with postmenopausal osteoporosis treated with raloxifene. Climateric. doi: 10.3109/13697137.2010.514628
9. A Giusti A Barone M Razzano M Oliveri M Pizzonia E Palummeri G Pioli 2009 Persistence with calcium and vitamin D in elderly patients after hip fracture J Bone Miner Metab 27 95 100 19018453 10.1007/s00774-008-0007-9 1:CAS:528:DC%2BD1cXhsFCgs73L
10. ES Siris PL Selby KG Saag F Borgström RM Herings SL Silverman 2009 Impact of osteoporosis treatment adherence on fracture rates in North America and Europe Am J Med 122 S3 S13 19187810 10.1016/j.amjmed.2008.12.002
11. SL Silverman DT Gold JA Cramer 2007 Reduced fracture rates observed only in patients with proper persistence and compliance with bisphosphonate therapies South Med J 100 1214 1218 18090964 10.1097/SMJ.0b013e31815a9685 (Pubitemid 350304827)
12. JR Curtis AO Westfall H Cheng K Lyles KG Saag E Delzell 2008 Benefit of adherence with bisphosphonates depends on age and fracture type: results from an analysis of 101,038 new bisphosphonate users J Bone Miner Res 23 1435 1441 18442318 10.1359/jbmr.080418
13. B Cortet O Benichou 2006 Adherence, persistence, concordance: do we provide optimal management to our patients with osteoporosis? Joint Bone Spine 73 1 7 10.1016/j.jbspin.2006.02.006 (Pubitemid 44848053)
14. D Weycker D Macarios J Edelsberg G Oster 2006 Compliance with drug therapy for postmenopausal osteoporosis Osteoporos Int 17 1645 1652 16862397 10.1007/s00198-006-0179-x 1:STN:280:DC%2BD28rotlahsA%3D%3D (Pubitemid 44477625)
15. V Ziller SP Zimmermann M Kalder M Ziller B Seker-Pektas L Hellmeyer P Hadji 2010 Adherence and persistence in patients with severe osteoporosis treated with teriparatide Curr Med Res Opin 26 675 681 20078188 10.1185/03007990903538409 1:CAS:528:DC%2BC3cXitVShs7o%3D
16. JD Adachi DA Hanley JK Lorraine M Yu 2007 Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study Clin Ther 29 2055 2067 18035204 10.1016/j.clinthera.2007.09.024 1:CAS:528:DC%2BD2sXhtlakt7jK (Pubitemid 350218118)
17. SA Foster KA Foley ES Meadows JA Johnston SS Wang GM Pohl SR Long 2011 Adherence and persistence with teriparatide among patients with commercial, Medicare, and Medicaid insurance Osteoporos Int 22 551 557 20798929 10.1007/s00198-010-1297-z 1:STN:280:DC%2BC3M7gslSqsA%3D%3D
18. BL Langdahl G Rajzbaum F Jakob D Karras O Ljunggren WF Lems A Fahrleitner-Pammer JB Walsh C Barker A Kutahov F Marin 2009 Reduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide: 18-month data from the European Forsteo Observational Study (EFOS) Calcif Tissue Int 85 484 493 19823760 10.1007/s00223-009-9299-6 1:CAS:528:DC%2BD1MXhsFSrt7fN
19. A Papaioannou G Ioannidis JD Adachi RJ Sebaldt N Ferko M Puglia J Brown A Tenenhouse WP Olszynski P Boulos DA Hanley R Josse TM Murray A Petrie CH Goldsmith 2003 Adherence to bisphosphonates and hormone replacement therapy in a tertiary care setting of patients in the CANDOO database Osteoporos Int 14 808 813 14523610 10.1007/s00198-003-1431-2 1:CAS:528:DC%2BD3sXosFWrsLg%3D (Pubitemid 37462130)
20. K Briot P Ravaud P Dargent-Molina M Zylberman S Liu-Leage C Roux 2009 Persistence with teriparatide in postmenopausal osteoporosis; impact of a patient education and follow-up program: the French experience Osteoporos Int 20 625 630 18661089 10.1007/s00198-008-0698-8 1:STN:280:DC%2BD1M7osVClsQ%3D%3D
21. NK Arden S Earl DJ Fisher C Cooper S Carruthers M Goater 2006 Persistence with teriparatide in patients with osteoporosis: the UK experience Osteoporos Int 17 1626 1629 16823543 10.1007/s00198-006-0171-5 1:STN:280: DC%2BD28rotlahsw%3D%3D (Pubitemid 44477622)
22. A Abhishek I Pande 2009 Teriparatide in men: persistence and geographical variation in the UK Osteoporos Int 20 1453 1454 19009329 10.1007/s00198-008- 0788-7 1:STN:280:DC%2BD1MvnsVCquw%3D%3D
23. M Mulgund KA Beattie AKO Wong A Papaioannou J Adachi 2009 Assessing adherence to teriparatide therapy, causes of nonadherence and effect of adherence on bone mineral density measurements in osteoporotic patients at high risk for fracture Ther Adv Musculoskel Dis 1 5 11 10.1177/1759720X09339551 1:CAS:528:DC%2BC3MXhs1els7zN